LIMN (Liminatus Pharma) FCF Margin %: 0.00% (As of Mar. 2026)


What is Liminatus Pharma FCF Margin %?

Liminatus Pharma LIMN +3.23% FCF Margin % is 0.00% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Liminatus Pharma ranks worse than 104275.18% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Liminatus Pharma's Free Cash Flow for the three months ended in Mar. 2026 was $-2.02 Mil. Liminatus Pharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Liminatus Pharma's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Liminatus Pharma's current FCF Yield % is -235.53%.

The historical rank and industry rank for Liminatus Pharma's FCF Margin % or its related term are showing as below:


LIMN's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Liminatus Pharma FCF Margin % Related Terms

Liminatus Pharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for Liminatus Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Liminatus Pharma FCF Margin % Chart

Liminatus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
FCF Margin %
0.00 0.00 0.00 0.00

Liminatus Pharma Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LIMN vs XBIO, PCSA, SILO: FCF Margin % Comparison

For the Biotechnology subindustry, Liminatus Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liminatus Pharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liminatus Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Liminatus Pharma's FCF Margin % falls into.


Liminatus Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Liminatus Pharma's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-9.976/0
= %

Liminatus Pharma's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.015/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Liminatus Pharma (LIMN) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Liminatus Pharma and its competitors. According to the industry distribution chart, Liminatus Pharma ranks #999999 out of 959 companies in the Biotechnology industry.
Is Liminatus Pharma's FCF Margin % too high?
Liminatus Pharma's current FCF Margin % is 0.00%. Based on the distribution chart, Liminatus Pharma ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Liminatus Pharma's FCF Margin % compare to XBIO and PCSA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #999999 out of 959 companies for FCF Margin %. This places Liminatus Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Liminatus Pharma and its competitors. Liminatus Pharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.